免疫实践咨询委员会关于使用二价COVID-19疫苗加强针的临时建议——美国,2022年10月
美国FDA修订紧急使用授权后,ACIP与CDC推荐所有年龄≥5岁人群在完成任何FDA批准或授权的单价基础免疫系列或单价加强针后至少2个月接种1剂二价mRNA加强针。二价疫苗包含祖先株与Omicron BA.4/BA.5株等量刺突mRNA。
要点
- ACIP与CDC推荐所有年龄≥5岁人群接种1剂二价mRNA加强针。
- 接种时机为完成任何FDA批准或授权的单价基础免疫系列或单价加强针后至少2个月。
- 二价mRNA疫苗含祖先株与Omicron BA.4/BA.5株等量刺突mRNA。
核心结论
- ACIP与CDC推荐所有年龄≥5岁人群在完成任何FDA批准或授权的单价基础免疫系列或单价加强针后至少2个月接种1剂二价mRNA加强针。
研究设计与样本
- 本文为ACIP发布的临时建议,基于FDA修订紧急使用授权及二价mRNA疫苗授权使用。
主要发现
- FDA修订紧急使用授权允许年龄≥5岁且完成任何FDA批准或授权基础免疫系列者接种二价mRNA疫苗作为加强针,并撤销单价COVID-19加强针的紧急使用授权。
- Pfizer-BioNTech与Moderna二价加强针均含祖先株与Omicron BA.4/BA.5株等量刺突mRNA。
关键数值与推荐
- 推荐所有年龄≥5岁人群接种1剂二价mRNA加强针,时机为完成任何FDA批准或授权的单价基础免疫系列或单价加强针后至少2个月。
临床怎么用
- 按ACIP与CDC推荐,对年龄≥5岁且已完成任何FDA批准或授权单价基础免疫系列或单价加强针满至少2个月者接种1剂二价mRNA加强针。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Four COVID-19 vaccines are currently approved for primary series vaccination in the United States under a Biologics License Application or authorized under an emergency use authorization (EUA) by the Food and Drug Administration (FDA), and recommended for primary series vaccination by the Advisory Committee on Immunization Practices (ACIP): 1) the 2- or 3-dose monovalent mRNA BNT162b2 (Pfizer-BioNTech, Comirnaty) COVID-19 vaccine; 2) the 2- or 3-dose monovalent mRNA mRNA-1273 (Moderna, Spikevax) COVID-19 vaccine; 3) the single-dose adenovirus vector-based Ad26.COV.S (Janssen [Johnson & Johnson]) COVID-19 vaccine; and 4) the 2-dose adjuvanted, protein subunit-based NVX-CoV2373 (Novavax) COVID-19 vaccine. The number of doses recommended is based on recipient age and immunocompromise status (1). For additional protection, FDA has amended EUAs to allow for COVID-19 booster doses in eligible persons (1). Because COVID-19 vaccines have demonstrated decreased effectiveness during the period when the Omicron variant (B.1.1.529) of SARS-CoV-2 predominated, bivalent booster doses (i.e., vaccine with equal components from the ancestral and Omicron strains) were considered for the express purpose of improving protection conferred by COVID-19 vaccine booster doses (2). During September-October 2022, FDA authorized bivalent mRNA vaccines for use as a booster dose in persons aged ≥5 years who completed any FDA-approved or FDA-authorized primary series and removed EUAs for monovalent COVID-19 booster doses (1). Pfizer-BioNTech and Moderna bivalent booster vaccines each contain equal amounts of spike mRNA from the ancestral and Omicron BA.4/BA.5 strains. After the EUA amendments, ACIP and CDC recommended that all persons aged ≥5 years receive 1 bivalent mRNA booster dose ≥2 months after completion of any FDA-approved or FDA-authorized monovalent primary series or monovalent booster doses.
引用
- Rosenblum HG, Wallace M, Godfrey M, et al. Interim Recommendations from the Advisory Committee on Immunization Practices for the Use of Bivalent Booster Doses of COVID-19 Vaccines - United States, October 2022. MMWR Morb Mortal Wkly Rep. 2022. PMID: 36355612. doi:10.15585/mmwr.mm7145a2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。